Ani Pharmaceuticals Inc. (ANIP)
Summary
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, a condition the company abbreviated as chronic NIU-PS.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.
Ani Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 20 | $1,302.83 | $1,609.78 | $306.95 | 23.56% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 123 | $9,523.98 | $9,977.69 | $453.71 | 4.76% |
| BG Bart Gancher Intech Investment Management LLC | 7,700 | $607,838 | $624,921.99 | $17,083.99 | 2.81% |
| NM Nir Messafi Deep Track Capita LLP | 600,000 | $40.22M | $48.59M | $8.37M | 20.81% |
| MD Michelle Dubey Yousif Capital Management LLC | 4,857 | $196,514.04 | $392,542.74 | $196,028.7 | 99.75% |
Ani Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Vamil Divan Guggenheim | 7,108.4 | $583,386.33 | $563,767.14 | -$19,619.19 | -3.36% |
Ani Pharmaceuticals Inc. (ANIP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ani Pharmaceuticals Inc. ever had a stock split?
Ani Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Nikhil Lalwani CEO | NASDAQ (NMS) Exchange | 00182C103 CUSIP |
| US Country | 970 Employees | - Last Dividend | 4 Jun 2012 Last Split | 5 May 2000 IPO Date |
Overview
ANI Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in the development, manufacturing, and marketing of both branded and generic prescription pharmaceuticals, primarily in the United States and Canada. With its incorporation in 2001, the company has established a significant presence in the pharmaceutical industry, headquartered in Baudette, Minnesota. It serves a wide range of customers including retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals, underpinning its comprehensive approach to healthcare solutions.
Products and Services
- Oral solid dose productsANI Pharmaceuticals excels in manufacturing a variety of oral solid dose products, such as tablets and capsules. These are designed for ease of use and effectiveness in treatment, catering to a wide range of therapeutic areas.
- Semi-solids, liquids, and topicalsThe company also produces semi-solid formulations, liquid medicines, and topical treatments. These products offer alternatives for patients requiring different delivery methods for their medications beyond traditional oral forms.
- Controlled substancesSpecializing in the highly regulated sector of controlled substances, ANI Pharmaceuticals demonstrates its commitment to maintaining stringent quality control and regulatory compliance, ensuring safe and reliable medications for conditions that require tightly controlled ingredients.
- Potent productsANI Pharmaceuticals has the capability to manufacture potent products that require special handling and manufacturing processes due to their high potency. These products are critical for treating more severe conditions, necessitating a higher level of expertise in their production.
- Contract development and manufacturing of pharmaceutical productsAside from its own product offerings, ANI Pharmaceuticals provides contract development and manufacturing services. This allows other companies to leverage ANI's expertise and facilities for the development and manufacturing of their pharmaceutical products, highlighting ANI's flexibility and capability in supporting the broader pharmaceutical industry.
